{"altmetric_id":1983359,"counts":{"readers":{"mendeley":24,"citeulike":0,"connotea":0},"facebook":{"unique_users_count":1,"unique_users":["147927835252207"],"posts_count":1},"news":{"unique_users_count":1,"unique_users":["medpage_today"],"posts_count":1},"total":{"posts_count":12},"twitter":{"unique_users_count":5,"unique_users":["TripPrimaryCare","JRBtrip","concaff","ARD_BMJ","TripRheumatol"],"posts_count":10}},"selected_quotes":["Golimumab 3-year safety update"],"citation":{"abstract":"To assess pooled golimumab safety up to year 3 of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) trials.","abstract_source":"pubmed","altmetric_jid":"4f6fa60b3cf058f610006a32","authors":["Jonathan Kay","Roy Fleischmann","Edward Keystone","Elizabeth C Hsia","Benjamin Hsu","Michael Mack","Neil Goldstein","J\u00fcrgen Braun","Arthur Kavanaugh"],"doi":"10.1136\/annrheumdis-2013-204195","first_seen_on":"2013-12-16T19:21:15+00:00","issns":["1468-2060"],"journal":"Annals of the Rheumatic Diseases","last_mentioned_on":1423167228,"links":["http:\/\/ard.bmj.com\/content\/early\/2013\/12\/16\/annrheumdis-2013-204195.short?rss=1","http:\/\/ard.bmj.com\/content\/early\/2013\/12\/16\/annrheumdis-2013-204195.full.pdf+html","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24344160","http:\/\/dx.doi.org\/10.1136\/annrheumdis-2013-204195","http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24344160?dopt=Abstract","http:\/\/ard.bmj.com\/cgi\/content\/short\/74\/3\/538?rss=1"],"pdf_url":"http:\/\/ard.bmj.com\/content\/early\/2013\/12\/16\/annrheumdis-2013-204195.full.pdf","pmid":"24344160","pubdate":"2013-12-16T00:00:00+00:00","publisher":"BMJ Publishing Group Ltd and European League Against Rheumatism","publisher_subjects":[{"name":"Clinical Sciences","scheme":"era"},{"name":"Immunology","scheme":"era"},{"name":"Public Health And Health Services","scheme":"era"}],"scopus_subjects":["Life Sciences","Medicine","Health Sciences","Immunology and Microbiology","Biochemistry, Genetics and Molecular Biology"],"startpage":"annrheumdis-2013-204195","subjects":["rheumatology"],"title":"Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis","type":"article","mendeley_url":"http:\/\/www.mendeley.com\/research\/golimumab-3year-safety-update-analysis-pooled-data-longterm-extensions-randomised-doubleblind-placeb-6"},"altmetric_score":{"score":11.5,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":11.5},"context_for_score":{"all":{"total_number_of_other_articles":4720494,"mean":5.6985437665106,"rank":378023,"this_scored_higher_than_pct":91,"this_scored_higher_than":4338746,"rank_type":"exact","sample_size":4720494,"percentile":91},"similar_age_3m":{"total_number_of_other_articles":127162,"mean":7.626133625876,"rank":12792,"this_scored_higher_than_pct":89,"this_scored_higher_than":114281,"rank_type":"exact","sample_size":127162,"percentile":89},"this_journal":{"total_number_of_other_articles":2361,"mean":5.9024355932203,"rank":300,"this_scored_higher_than_pct":87,"this_scored_higher_than":2059,"rank_type":"exact","sample_size":2361,"percentile":87},"similar_age_this_journal_3m":{"total_number_of_other_articles":136,"mean":9.6728888888889,"rank":31,"this_scored_higher_than_pct":77,"this_scored_higher_than":105,"rank_type":"exact","sample_size":136,"percentile":77}}},"demographics":{"poster_types":{"member_of_the_public":3,"practitioner":1,"science_communicator":1},"users":{"twitter":{"cohorts":{"Members of the public":3,"Practitioners (doctors, other healthcare professionals)":1,"Science communicators (journalists, bloggers, editors)":1}},"mendeley":{"by_status":{"Professor > Associate Professor":2,"Librarian":1,"Researcher":5,"Student  > Doctoral Student":1,"Student  > Ph. D. Student":1,"Student  > Postgraduate":3,"Student  > Master":3,"Other":5,"Student  > Bachelor":2,"Lecturer":1},"by_discipline":{"Medicine and Dentistry":19,"Psychology":1,"Economics, Econometrics and Finance":1,"Agricultural and Biological Sciences":1,"Nursing and Health Professions":2}}},"geo":{"twitter":{"GB":1,"IE":1},"mendeley":{"CO":1,"BR":1,"GB":1}}},"posts":{"news":[{"title":"Simponi Safe for RA at 3-Year Mark (CME\/CE)","url":"http:\/\/www.medpagetoday.com\/Rheumatology\/Arthritis\/43532","license":"public","citation_ids":[1983359],"posted_on":"2013-12-20T15:30:00+00:00","summary":"(MedPage Today) -- The tumor necrosis factor (TNF) inhibitor golimumab (Simponi) continued to show safety similar to that of the older anti-TNF agents across all rheumatic indications through 3 years of follow-up, an analysis of pooled data showed.","author":{"name":"MedPage Today","url":"http:\/\/www.medpagetoday.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/262\/normal\/Screen_Shot_2016-02-09_at_10.51.03.png?1455015082"}}],"twitter":[{"url":"http:\/\/twitter.com\/TripPrimaryCare\/status\/449459696475176960","license":"public","citation_ids":[1983359],"posted_on":"2014-03-28T08:15:16+00:00","author":{"name":"Trip Primary Care","image":"https:\/\/pbs.twimg.com\/profile_images\/429598293052497922\/tEinrVIC_normal.jpeg","description":"All the latest primary care evidence, added to the Trip Database. Tweets are not endorsements","id_on_source":"TripPrimaryCare","tweeter_id":"2199494760","geo":{"lt":null,"ln":null},"followers":2134},"tweet_id":"449459696475176960"},{"url":"http:\/\/twitter.com\/JRBtrip\/status\/448480898032603136","license":"public","rt":["TripRheumatol"],"citation_ids":[1983359],"posted_on":"2014-03-25T15:25:53+00:00","author":{"name":"Jon Brassey","url":"http:\/\/www.tripdatabase.com","image":"https:\/\/pbs.twimg.com\/profile_images\/848963179799621632\/13FZ5NG4_normal.jpg","description":"Personal account. Also see @tripdatabase and @rapidreviews_i","id_on_source":"JRBtrip","tweeter_id":"14359728","geo":{"lt":51.45523,"ln":-2.59665,"country":"GB"},"followers":2107},"tweet_id":"448480898032603136"},{"url":"http:\/\/twitter.com\/concaff\/status\/448480955003863040","license":"public","rt":["TripRheumatol"],"citation_ids":[1983359],"posted_on":"2014-03-25T15:26:06+00:00","author":{"name":"Conor Caffrey","url":"http:\/\/www.conorcaffrey.wordpress.com","image":"http:\/\/pbs.twimg.com\/profile_images\/1238222983\/namib3a_normal.jpg","description":"Writer on Science and Medicine. Content Curator. Tweets on medical research, digital health, genes, brains,  pain, diabetes, etc.","id_on_source":"concaff","tweeter_id":"21090777","geo":{"lt":"52.865196","ln":"-7.9794599","country":"IE"},"followers":2008},"tweet_id":"448480955003863040"},{"url":"http:\/\/twitter.com\/JRBtrip\/status\/449466630842900480","license":"public","rt":["TripPrimaryCare"],"citation_ids":[1983359],"posted_on":"2014-03-28T08:42:50+00:00","author":{"name":"Jon Brassey","url":"http:\/\/www.tripdatabase.com","image":"https:\/\/pbs.twimg.com\/profile_images\/848963179799621632\/13FZ5NG4_normal.jpg","description":"Personal account. Also see @tripdatabase and @rapidreviews_i","id_on_source":"JRBtrip","tweeter_id":"14359728","geo":{"lt":51.45523,"ln":-2.59665,"country":"GB"},"followers":2107},"tweet_id":"449466630842900480"},{"url":"http:\/\/twitter.com\/TripPrimaryCare\/status\/457204535681757184","license":"datasift","citation_ids":[1983359],"posted_on":"2014-04-18T17:10:30+00:00","author":{"name":"Trip Primary Care","image":"https:\/\/pbs.twimg.com\/profile_images\/429598293052497922\/tEinrVIC_normal.jpeg","description":"All the latest primary care evidence, added to the Trip Database. Tweets are not endorsements","id_on_source":"TripPrimaryCare","tweeter_id":"2199494760","geo":{"lt":null,"ln":null},"followers":2134},"tweet_id":"457204535681757184"},{"url":"http:\/\/twitter.com\/JRBtrip\/status\/457246616643465216","license":"datasift","rt":["TripPrimaryCare"],"citation_ids":[1983359],"posted_on":"2014-04-18T19:57:43+00:00","author":{"name":"Jon Brassey","url":"http:\/\/www.tripdatabase.com","image":"https:\/\/pbs.twimg.com\/profile_images\/848963179799621632\/13FZ5NG4_normal.jpg","description":"Personal account. Also see @tripdatabase and @rapidreviews_i","id_on_source":"JRBtrip","tweeter_id":"14359728","geo":{"lt":51.45523,"ln":-2.59665,"country":"GB"},"followers":2107},"tweet_id":"457246616643465216"},{"url":"http:\/\/twitter.com\/TripRheumatol\/status\/453651152303706113","license":"datasift","citation_ids":[1983359],"posted_on":"2014-04-08T21:50:37+00:00","author":{"name":"Jon Brassey","url":"http:\/\/www.tripdatabase.com","image":"http:\/\/pbs.twimg.com\/profile_images\/429598728173797376\/TCLU8wWe_normal.jpeg","description":"All the latest rheumatology evidence, added to the Trip Database. Tweets are not endorsements","id_on_source":"TripRheumatol","tweeter_id":"2299238034","followers":231},"tweet_id":"453651152303706113"},{"url":"http:\/\/twitter.com\/TripRheumatol\/status\/457091218753589248","license":"datasift","citation_ids":[1983359],"posted_on":"2014-04-18T09:40:13+00:00","author":{"name":"Jon Brassey","url":"http:\/\/www.tripdatabase.com","image":"http:\/\/pbs.twimg.com\/profile_images\/429598728173797376\/TCLU8wWe_normal.jpeg","description":"All the latest rheumatology evidence, added to the Trip Database. Tweets are not endorsements","id_on_source":"TripRheumatol","tweeter_id":"2299238034","followers":231},"tweet_id":"457091218753589248"},{"url":"http:\/\/twitter.com\/TripRheumatol\/status\/448386362954096640","license":"public","citation_ids":[1983359],"posted_on":"2014-03-25T09:10:14+00:00","author":{"name":"Jon Brassey","url":"http:\/\/www.tripdatabase.com","image":"http:\/\/pbs.twimg.com\/profile_images\/429598728173797376\/TCLU8wWe_normal.jpeg","description":"All the latest rheumatology evidence, added to the Trip Database. Tweets are not endorsements","id_on_source":"TripRheumatol","tweeter_id":"2299238034","followers":231},"tweet_id":"448386362954096640"},{"url":"http:\/\/twitter.com\/ARD_BMJ\/status\/412663655952420864","license":"public","citation_ids":[1983359],"posted_on":"2013-12-16T19:20:57+00:00","author":{"name":"ARD","url":"http:\/\/ard.bmj.com","image":"https:\/\/pbs.twimg.com\/profile_images\/784372806297460737\/0G3PFep__normal.jpg","description":"ARD is an international peer-reviewed journal committed to promoting the highest standards of scientific exchange. Top impact factor in the rheumatology field","id_on_source":"ARD_BMJ","tweeter_id":"138744646","geo":{"lt":null,"ln":null},"followers":3203},"tweet_id":"412663655952420864"}],"facebook":[{"title":"Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=913789795332670&id=147927835252207","license":"public","citation_ids":[1983359],"posted_on":"2015-02-05T20:13:48+00:00","summary":"ObjectiveTo assess pooled golimumab safety up to year 3 of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) trials. MethodsGolimumab 50 and 100 mg, administered subcutaneously (SC) every 4 weeks (q4wk), were \u2026","author":{"name":"Annals of the Rheumatic Diseases (ARD)","url":"https:\/\/www.facebook.com\/147927835252207","facebook_wall_name":"Annals of the Rheumatic Diseases (ARD)","image":"https:\/\/graph.facebook.com\/147927835252207\/picture","id_on_source":"147927835252207"}}]}}